Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41375-023-02121-6 | DOI Listing |
Publication Analysis
Top Keywords
interleukin-15 -21-activated
4
-21-activated donor-derived
4
donor-derived cell
4
cell infusion
4
infusion haploidentical
4
haploidentical hct
4
hct high-risk
4
high-risk aml
4
aml mds-a
4
mds-a cohort
4
Similar Publications
Interleukin-15 and -21-activated, donor-derived NK cell infusion after haploidentical HCT in high-risk AML and MDS-a cohort analysis.
Leukemia
February 2024
Ingenium Therapeutics, Daejeon, Republic of Korea.
The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial.
Leukemia
April 2023
Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
Clinical effect of donor-derived natural killer cell infusion (DNKI) after HLA-haploidentical hematopoietic cell transplantation (HCT) was evaluated in high-risk myeloid malignancy in phase 2, randomized trial. Seventy-six evaluable patients (aged 21-70 years) were randomized to receive DNKI (N = 40) or not (N = 36) after haploidentical HCT. For the HCT conditioning, busulfan, fludarabine, and anti-thymocyte globulin were administered.
View Article and Find Full Text PDF